NEW YORK, September 11, 2018 /PRNewswire/ --
CannabisNewsWire Editorial Coverage
Cannabis companies are seeing substantial growth, with the popularity of cannabidiol (CBD) playing a significant part in their positive outlook.
- CBD is an active ingredient in cannabis.
- It can provide health benefits without the psychotropic effects of other cannabis chemicals.
- This has led to a growth in companies selling CBD treatments, sometimes alongside more conventional wellness products.
Youngevity International, Inc. (NASDAQ:YGYI) (YGYI Profile) is one of these companies, having recently expanded its range of products to include CBD therapies for muscle pain, sleeplessness and mood improvement. GW Pharmaceuticals Plc (NASDAQ:GWPH) has created a CBD treatment for child-onset epilepsy and received approval from the U.S. Food and Drug Administration for its sale as a medicinal product. Tilray, Inc. (NASDAQ:TLRY) has also developed a cannabis-derived epilepsy treatment, even as it makes deals to expand its distribution network in Canada. Aphria, Inc. (OTC:APHQF) (TSX:APH) has seen a steady rise in profits based on its cannabis work and is now working with branding specialists to capitalize on its opportunities. Isodiol International, Inc. (OTC:ISOLF) (CSE:ISOL) is providing not only a range of CBD products but also a platform for patients to connect with doctors to help manage cannabis-based medical treatment.
Cannabis Growth Continues
The past few years have seen substantial growth in the cannabis industry. As the plant's legalization spreads, an increasingly diverse range of businesses have appeared to fill the needs of a growing wellness market. From hydroponic supply companies to seed providers, the industry is expanding at a rapid pace, and at its heart are the cannabis companies themselves, several of which have seen their stocks soar.
One of the reasons for recent growth is the development of a market in cannabidiol (CBD) drugs and wellness products. One of the active ingredients in cannabis, CBD is being used in a wide range of treatments to help with everything from epilepsy to mental alertness. A growing body of research and increasing range of uses have seen CBD oil become a significant part of the cannabis market, distinct from recreational marijuana. For companies invested in CBD, this trend is providing a fresh surge of growth.
The Power of Cannabidiol
A growing number of companies are producing and supplying CBD products - not just specialist firms, but other suppliers such as lifestyle company Youngevity International, Inc. (NASDAQ:YGYI). So what's the fuss about?
CBD is one of the most prominent active ingredients in cannabis plants. Unlike tetrahydrocannabinol (THC), CBD does not cause users to get high, but it can have other effects on the body and mind. Those beneficial effects have led to CBD's rising popularity for use in a variety of medicines and wellness products as researchers have learned more about it.
The distinction between CBD and THC is an important one. In some jurisdictions, industrial hemp, a type of cannabis plant that includes CBD but non-noteworthy amounts of THC, can be grown in circumstances where marijuana can't. The legality of CBD products is different from that of cannabis cultivation itself in some places. Even in places where cannabis is legal for both medical and recreational uses, CBD is preferable to many health-conscious consumers who want its health effects without getting high.
It's this potential that has drawn companies such as Youngevity to CBD. This market is expected to see tremendous growth based on forecasts for a range of uses beyond oils, such as CBD's inclusion in food, drink, cosmetics and emerging health products. That's a pretty impressive reason for companies to take an interest in CBD, whether they're experienced cannabis insiders or newcomers such as Youngevity.
Wider Market Growth
Medical cannabis is now legal in more than half of North America. Legal recreational use has been enacted within nine states and the District of Columbia in the United States, and it will premiere nationwide in Canada in October. The cannabis plant's ardent fan base is increasing public awareness and a growing acceptance of the potential benefits of products derived from it. Companies are moving to make the most of the opportunity as a previously frowned-on and illegal industry shifts into the mainstream.
This means that Youngevity's cannabis-derived products will benefit from a wave of public awareness, publicity and market growth. The global value of this market was estimated at $7.7 billion in 2017, and it's been predicted to reach $34.1 billion by 2021.
That growing market means that there's now space for CBD products both on the shelves of high street stores and in the inventory of companies such as Youngevity.
Youngevity's first entry into this market is the HempFX™ product line, introduced at the company's 2018 convention in San Diego, Calif. A set of three distinct hemp-derived CBD oil products under the HempFX banner use organically grown products in proprietary formulas to help users through their day. The products include Soothe™, a blend of botanicals designed to relieve muscles by calming aches and pains; Uplift™, which combines CBD with St. John's Wort to improve cognitive performance and mood; and Relax™, which combines CBD with a variety of herbs and melatonin to bring relaxation and a better night's sleep.
This diverse range of uses shows why CBD is becoming so popular. By applying it to a variety of wellness issues, companies are able to market their products to a broad range of consumers, increasing sales and awareness.
Youngevity CEO Steve Wallach highlighted the strong potential link between CBD and broader trends in healthy living. "We firmly believe in plant-based nutrition, and hemp-derived (CBD) oil perfectly complements our product development philosophy. Entering this market, which is growing almost exponentially, also should offer a tremendous advantage to our many distributors around the world," he stated in the company's news release announcing the HempFX line.
The Power of Existing Pipelines
Wallach's reference to distributors highlights why a company such as Youngevity is so well-positioned to benefit from the surge in CBD. New companies set up to cater to the CBD market have to build their sales pipelines from scratch, whereas established operators already have those pipelines in place. Youngevity's massive network of direct sellers means that it has an immediate way of getting new products into the hands of consumers. Experience derived from 21 years of development has provided the company with the tools it needs to carve out its place in the market.
Being on-brand is important to such a move. Not just any company can jump into CBD and expect customers and distributors to come along with it. But according to Wallach, this isn't a problem for Youngevity.
"Hemp-derived cannabidiol aligns with what we do very well," he stated. "We've taken what we know about essential nutrients, along with decades of knowledge specializing in natural, plant-based nutrition and their most beneficial nutrients, and put that knowledge to work to develop high-end cannabidiol products."
More Companies Take Up CBD
While CBD is often used in over-the-counter medicines and wellness products, it is also finding use in prescription medicines. GW Pharmaceuticals Plc (NASDAQ:GWPH) has created a CBD-based medicine to tackle child-onset epilepsy, a condition that can make a normal life almost unmanageable for the children it affects. This treatment has been approved by the FDA, making it the first cannabis plant-based prescription medicine to be legalized by the U.S. federal government (once the Drug Enforcement Administration reclassifies CBD, as expected this month in response to the FDA's decision).
A global leader in the medical cannabis market, Tilray, Inc. (NASDAQ:TLRY) works in research, cultivation, processing and distribution, providing cannabis extracts and flowers to patients, researchers and medical professionals on five continents. As Canada prepares for growth in the cannabis market following legalization, the company has made deals with Canadian partners to sell its products into that market. It has also developed a CBD and THC oil that has shown promising results in tackling drug-resistant epilepsy.
One of the more successful companies in the cannabis sector, Aphria, Inc. (OTCQB:APHQF) (TSX:APH) saw its profits and revenues rise steadily through 2016 and 2017. Aphria recently signed a letter of intent to form a joint venture with Perennial, Inc., in which the companies will collaborate on developing products for the Canadian cannabis market. Perennial's expertise in strategic brand development will help Aphria reach more customers with its leading cannabis-based products, expanding its presence in one of the world's most important cannabis markets.
Isodiol International, Inc. (OTCQB:ISOLF) (CSE:ISOL) is focused on CBD product development, with a range of offerings that includes skin cream, pain management and help with sleeping. It has recently expanded beyond its core products into support for those using cannabis-derived medicines through the creation of ISOCare. This secure platform will help to connect patients, their family doctors and physicians working with cannabis to ensure that patients receive the best possible longitudinal care.
The health benefits of cannabis and its derivatives are increasingly widely recognized. With huge potential for growth over the next few years, CBD and cannabis are drawing customers and companies like never before.
For more information about Youngevity International, please visit Youngevity International, Inc. (NASDAQ:YGYI).
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with CNW or any company mentioned herein. The commentary, views and opinions expressed in this release by CNW are solely those of CNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW and FNM for any investment decisions by their readers or subscribers. CNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.
CNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW and FNM undertake no obligation to update such statements.
CannabisNewsWire (CNW) & NetworkNewsWire (NNW) are proud to be affiliated partners of the Investor Brand Network (IBN)
Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Brand Network (IBN) http://www.InvestorBrandNetwork.com
Corporate Communications Contact:
FN Media Group, LLC